In addition to the primary complement deficiencies, we identified two groups with acquired complement deficiency, those with immune disorders leading to secondary complement deficiency and iatrogenic cases in patients receiving Eculizumab, a humanised monoclonal complement C5 inhibitor. This evidence concerns the gene C5 and complement deficiency.